Glucagon (pmol/L) 7 (<5-23) 6 (c5-20) 12 (<5-18) 12 (<5-130). TNFa (U/mL) < 7 (<7-26) < 7 (<7-41) 16 (<7-81)b 16 (<7-500)b Insulin (mU/L) 18 (2-82) 16 (10-39) 12 (2-86) 19 (8-170) Glucose (mmol/L) 4.4 (3.2-8.0) 4.7 (3.3-7.0) 3.3 (2.1-6.9) 5.1 (2.6-9.1) Cortisol (nmol/L) 320 (50-820) 350 (290-910) 360 (150-810) 370 (30-1060) TSH (mU/L) 0.9 (0.4-7.5) 1.5 (0.6-6.6) 1.6 (0.5-4.7) 2.1 (0.4-9.6) Growth hormone (mU/L) 3 -3 (1.9-17.0)  2.5 (1.5-35.0)  7-0 (2.3-9.0)  4.0 (1.3-36.0) 'Significantly higher than concentrations in patients with stages I , I1 and I11 disease (P<0.05) . 'Significantly higher than concentrations in patients with stages I and I1 disease (P< 0-05).
SUMMARY. Fasting blood samples were collected from 83 patients with histologically proven breast cancer and analysed for plasma glucagon, serum immunoreactive tumour necrosis factor (TNFa), insulin, glucose, growth hormone, cortisol and TSH. Samples from patients with known diabetes mellitus or thyroid disease, and those on parenteral nutrition or with evidence of infection were excluded as were patients who had a history of weight loss through dieting or who were anorexic.
Fasting plasma glucagon, serum cortisol and immunoreactive TNFa concentrations in patients with stage IV breast cancer who had developed weight loss were significantly higher than those in patients with stage IV disease who had not developed weight loss. There were no significant differences in the fasting serum concentrations of insulin, glucose, growth hormone and TSH between the two patient groups.
The association between weight loss in stage IV breast cancer and increased concentrations of plasma glucagon, serum cortisol and TNFa suggests a possible role for these hormonal factors in the development of cancer cachexia.
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Severe weight loss and debilitative wasting of lean body mass, termed cachexia, frequently complicate the treatment of patients suffering from malignancy. Some data indicate that as many as 30% of cancer patients die from cachexia rather than tumour burden.'" While it is likely that a variety of mechanisms participate in the pathogenesis of cachexia, and that cachexia adversely affects prognosis, the aetiology of this syndrome is not known. 4 Although a significant number of patients with malignant disease are anorexic5 and have a reduced food intake possibly related to abnormalities in the sensation of tasteS or in the central control of appetite,6 most studies have shown that caloric intake is not significantly reduced in cancer patients with Abnormalities of intermediary metabolism in cancer patients are well described. They include increased Cori cycle activity,* impaired glucose tolerance and insulin re~istance,~J~ a tendency to Correspondence: Dr M L Knapp. mobilize and metabolize fat,lL increased gluconeogenesis from alanineI2 and depletion of intramuscular energy substrates.I3 All these metabolic processes could contribute to the development of cancer cachexia. However, the hormonal mechanisms behind these metabolic changes have yet to be elucidated. The present study was therefore undertaken to ascertain whether there was an association between weight loss and blood levels of immunoreactive tumour necrosis factor a (TNFa), insulin, glucagon, growth hormone, cortisol and thyroid-stimulating hormone (TSH) in breast cancer.
PATIENTS AND METHODS

Patients
Blood samples were collected from 83 patients with histologically proven breast cancer who were attending the oncology clinic at the Westminster Hospital, London, or the breast clinic at St Peter's Hospital, Chertsey. Prior to the study, ethical committee approval for the collection of samples from these patients had been obtained. Patients were staged according to the TNM (tumour, node and metastasis) classification. The history of weight loss was assessed from the patients weight recorded at each visit to the clinic. Patients were considered to have a history of weight loss if they had lost more than 10070 of their body weight over the previous 6 months. Patients with known diabetes mellitus or thyroid disease, and those on parenteral nutrition or with clinical evidence of infection were excluded from this study as were patients who had a history of weight loss because they were intentionally dieting or who were anorexic. A summary of the clinical information obtained on patients for this study is shown in Table 1 .
Venous blood (10 mL) was collected between 0830 and 1030 h into plain glass (7.5 mL) and lithium heparin (2.5 mL) tubes after a 12 h fast. The heparinized sample was centrifuged immediately at lOOOg for 15 min at 4 "C and frozen at -70 "C for glucagon assay. The serum sample was allowed to clot for 15min at 4°C then similarly centrifuged and stored at -70 "C in 0 -5 m L aliquots for assay of TNFa, insulin, glucose, growth hormone, cortisol and TSH.
Glucagon and insulin assays
Glucagon and insulin were determined by double antibody radioimmunoassay14-15 using reagents from ICN Biomedicals Inc. (California, USA). For the glucagon assay, antibody cross reaction with enteroglucagon, insulin and gastrin was < 0.002%. The between batch imprecision (CV) was 1 1 .3 and 8 3% at glucagon concentrations of 20 and 150 pmol/L. respectively, sensitivity was 5 pmol/L, with a fasting reference range up t o 40pmol/L. For the insulin assay, antibody cross reaction with proinsulin, C peptide and glucagon was 19, 0.0003 and 0.09%, respectively. The between batch imprecision (CV) was 12.3 and 7.1% at insulin concentrations of 7 -5 and 25 1 mU/L, respectively, sensitivity was 1 mU/L with a fasting reference range up to 45 mU/L.
Tumour necrosis factor a assay
Immunoreactive TNFa was measured by enzymelinked immunosorbent assay (ELISA) on microtitre plates. Synthetic recombinant human TNFa standard lot 87/650, rabbit polyclonal anti-TNFa antiserum lot R32 and mouse monoclonal anti-TNFa antiserum lot 1014 was generously provided by Dr A Meager, National Institute of Biological Standards and Controls, South Mimms, UK. Alkaline phosphatase-linked sheep anti-mouse IgG from Sigma Chemical Company (Poole, UK) was used as labelled antibody. The assay showed no detectable cross reactivity to TNFP or interleukin 1 and correlated with cytotoxic bioassay for recombinant TNFa. The sensitivity was 7 U/mL, with between batch imprecision of 9.5% at a level of 25 U/mL. Using this assay, serum TNFa was undetectable (< 7 U/mL) in normal healthy individuals.
The following reagents were required: coating buffer (sodium carbonate, pH 9-6, 50 mmol/L; assay/wash buffer (phosphate buffer, pH 7.2, 50 mmol/L, containing sodium chloride (150 mmol/L) and Tween 20 (0.5% v/v)); blocking buffer (assay/wash buffer plus human serum albumin (1% w/v)); and substrate buffer (diethanolamine, pH 9-8,0.5 mol/L, containing Mg C1, (0.5 mmol/L)).
Rabbit polyclonal anti-TNFa antiserum was diluted 1 in 100 with coating buffer before use.
Recombinant TNFa standard was diluted in assay/wash buffer to give final concentrations of 8, 16, 31, 63, 125, 250, 500 and lOOOU/mL.
The protocol was as follows Diluted polyclonal anti-TNFa (50 pL) was added to each microtitre plate well and incubated at + 4 "C overnight
The wells were then washed (~3 ) with assay/washing buffer Blocking buffer was added (100 pL/well) and incubated at 37 "C for 3 h Wash step as (ii) Sample or standard was added (50 pL/well in duplicate) and incubated at + 4 "C overnight Wash step as (ii) Monoclonal anti-TNFa was added (50 pL/ well) and incubated at + 4 "C overnight Wash step as (ii) Alkaline phosphatase-linked sheep antimouse IgG (diluted 1 in 100 in assay/wash buffer) was added (100 pL/well) and incubated at 20 "C for 3 h Wash step as (ii) 4nitrophenylphosphate (10 mmoVL) in substrate buffer was added (100 pL/well). After incubation at 20 "C for 1 h, the reaction was stopped by adding 3 M NaOH (50 pL/well) The microtitre plate was read on a Titerteck Multiskan plate reader at 405 nm (xiii) A standard curve was plotted on log-linear paper and the concentration of TNFa in the samples was read from the standard curve
Growth hormone assay
Growth hormone was measured by a two-site immunoradiometric assayI6 using reagents supplied by Immunodiagnostic Systems Ltd (IDS, Tyne & Wear, UK). The between batch imprecision (CV) was 12-3 and 9.2% at growth hormone concentrations of 5 and 20 mU/L, respectively, sensitivity was 1 mU/L with a fasting reference range up to 10 mU/L.
Cortisol assay
Cortisol was estimated by radioimm~noassay'~ using reagents supplied by IDS Ltd. The between batch imprecision (CV) was 7 -1 and 9.8% at cortisol concentrations of 175 and 550 nmol/L, respectively. The 0800 h reference range for serum cortisol was 150 to 650nmoVL.
TSH assay
TSH was determined by solid-phase, two-site fluoroimmunometric assay (Delfia)ls using reagents supplied by Pharmacia Ltd (Milton Keynes, UK). The between batch imprecision (CV) was 5 -4 and 3.5% at TSH concentrations of 1 -1 and 11 .3 mU/L, respectively, sensitivity was 0.02 mU/L with a reference range of 0.4 to 5.0 mU/L.
Data analysis
The Mann-Whitney U test was used to assess the significanceof anydifferencesinanalyteconcentration associated with stage of disease, site(s) of metastases, treatment or weight loss in the breast cancer patients. Correlation between concentrations of the various analytes was assessed by least squares linear regression. Deming's correction for slope was not applied because Sex/Sx was less than 0.2.I9 The 2 test was used to assess whether there was a significant difference in the number of patients in different treatment groups or with metastases in different sites between those patients with stage IV disease who had significant weight loss and those patients who did not have weight loss.
RESULTS
Fasting plasma glucagon concentrations were significantly higher in stage IV patients than in patients with stages I, I1 and 111 disease (P<O-O5,
Mann-Whitney U test). Similarly, fasting serum immunoreactive TNFo levels were significantly higher in stage I11 and IV patients than in patients with stage I and I1 disease (P<O.O5). There was no significant difference in the fasting serum concentrations of insulin, glucose, growth hormone, cortisol and TSH between patients with stages I, 11, 111 and IV disease ( Table 2 ). The fasting serum concentration of immunoreactive TNFo, insulin, cortisol, growth hormone, TSH and plasma glucagon showed no significant correlations with each other in the breast cancer patients whether the data were analysed separately by stage of disease or with all stages combined. There was, however, a significant positive correlation between fasting serum glucose and insulin concentrations for all stages of disease (y=4-37 + 0 . 0 2 1~: r = 0-54 :P< 0.001). Fasting serum glucose did not correlate with the fasting concentrations of any other measured analyte. Fasting concentrations of these analytes in patients receiving radiotherapy or chemotherapy were not significantly different from those in patients who had not received radiotherapy or chemotherapy. Similarly, there was no significant difference between the fasting concentrations in those patients on anti-oestrogen therapy or steroid therapy and those patients not on anti-oestrogen or steroid therapy (P>O. 1).
The relationship between analyte concentration and weight loss was investigated only for patients
with stage IV disease as only 3/36 patients with stage I, I1 and 111 disease had significant weight loss whereas 24/47 (5 1%) of patients with stage IV disease had significant weight loss. There was no significant difference in the fasting serum concentrations of insulin, glucose, growth hormone and TSH between patients with stage IV breast cancer who had significant weight loss and those with stage IV disease who did not have weight loss ( P > 0 . 2 , in all cases). However, fasting concentrations of plasma glucagon and serum cortisol were significantly higher in stage IV patients who had weight loss than in those who did not have weight loss (Figs 1 and 2, respectively). Furthermore, serum immunoreactive TNFa concentrations in stage IV patients with more than 20% loss of body weight over the previous 6 months were significantly higher than concentrations in stage IV patients without weight loss (Fig. 3) .
In patients with stage IV disease, there was no significant difference in the numbers of patients with bony metastases or liver metastases in the weight loss and no weight loss groups. Similarly, the numbers of patients receiving chemotherapy, radiotherapy, anti-oestrogen or steroid therapy were not significantly different in the weight loss and no weight loss groups (P>O.l in all cases).
DISCUSSION
This study has shown that fasting plasma glucagon, serum cortisol and immunoreactive TNFa concentrations are significantly higher in stage IV breast cancer patients who have weight loss than in stage IV breast cancer patients who do not have weight loss. Furthermore, fasting plasma glucagon and serum immunoreactive TNFa levels increased significantly with increasing stage of disease implying a relationship between the degree of elevation of glucagon and TNFa and the severity of the pathological process.
The known biological activities of glucagon and cortisol in stimulating hepatic gluconeogenesis, muscle proteolysis and adipose tissue lipolysisMU could provide a mechanism by which increased blood levels of these hormones could cause weight loss in stage IV breast cancer patients. Injection of recombinant TNFa into both rats and human cancer patients has been shown to cause markedly increased muscle amino acid efflux with increased hepatic uptake of the gluconeogenic amino acids alanine and glutamine, resulting in depletion of muscle protein stores and increased hepatic g l u c o n e o g e n e~i s .~~~~~ Furthermore, injection of recombinant human TNFa results in a concomitant rise in plasma glucagon levels in rats,24 serum cortisol in man25 and both glucagon and cortisol in dogs. 26 The present study, however, did not demonstrate a correlation between TNFa and glucagon, TNFa and cortisol or glucagon and cortisol, suggesting that the rises in TNFa, glucagon and cortisol are at least in part independent of one another and possibly controlled by another common factor. It is possible that TNFa could indirectly stimulate cortisol and glucagon release by increasing interleukin 1 p r o d~c t i o n .~~ Direct experimental evidence implicating TNFa in cachexia has come from the work of Tracey . .
. . .
L FIGURE 3 . The relationship between serum immunoreactive TNFa levels and weight loss in patients
with stage IV breast cancer. Median level -. et aL4 and Oliff et a1.= Rats given twice daily intra-peritoneal injections of TNFa exhibited significant weight loss within 10 days of inje~tion.~ Tumours producing human TNFa transplanted into nude mice caused severe progressive weight loss with the pathologic and histologic features of cancer associated cachexia in 87% of animals whereas control mice bearing tumours that did not produce TNFa did not develop cachexia. 28 Administration of recombinant human TNFa as a continuous 5 day IV infusion into human cancer patients did not, however, result in cachexia.B It is possible that a longer exposure to increased circulating levels of TNFa is necessary to induce cachexia in man.
TNFa-like immunoreactivity has been detected previously in the serum of a significant number of cancer p a t i e n t~~.~~ and found to be produced by the peripheral blood mononuclear cells of such patient^.'^ However, two previous studies failed to detect any TNFa in the serum of patients with cancer cachexia using either a sandwich ELISA assay33 or a cytotoxic assay." However, in neither study were samples from patients with breast cancer examined and in the second study only two samples were analysed from patients with cachexia. It is possible that the discrepancies in results are at least partly due to differences in assay sensitivity and specificity. Using a two site ELISA assay, it has been shown previously that patients with lymphomas and active small cell lung cancer have undetectable levels of TNFa i m m~n o r e a c t i v i t y .~~-~~ Stage of disease as well as tumour type. may also be a critical factor in determining whether TNFa will be detected and in the present study no patients with early disease had grossly raised levels. Clearly much additional careful work must be undertaken to characterize precisely the structure of the proteins measured by different assays and how they correlate with the biological activity of intact TNFa.
In conclusion, the significant association between fasting plasma glucagon, serum cortisol, immunoreactive TNFa and weight loss in stage IV breast cancer patients suggests a possible role for these hormonal factors in the development of cancer cachexia. Increased production of TNFa in breast cancer could be due to increased TNFa release by activated macrophages in response to tumour cells.32 Increased production of glucagon and cortisol either could be a consequence of increased TNFa s y n t h e s i~~~.~~ or could be mediated via increased production of catecholamines associated with ~tress.~'*~* The failure of serum insulin concentrations to rise in response to an increment in plasma glucagon concentration may contribute further to the enhanced catabolic effects of these hormones and could also be mediated via increased production of catech~larnines.~~ Unfortunately, no index of catecholamine secretion was measured in the present study.
It must be remembered that weight loss per se in 'healthy' starving subjects may be associated with profound changes in neuro-endocrine function with increases in the levels of catabolic hormones.40 It could be argued that the increased levels of glucagon and cortisol observed in the stage IV breast cancer patients with weight loss were a consequence of the weight loss and not the cause of it. However, patients with anorexia were excluded from the present study. Furthermore, most studies have shown that caloric intake is not significantly reduced in cancer patients with
The present study has identified hormonal factors that may have a role to play in the development of cancer cachexia. A better understanding of these factors is clearly required before rational therapeutic approaches can be developed.
